Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
RDY Stock Chart & Stats
$13.99
$0.11(0.67%)
At close: 4:00 PM EST
$13.99
$0.11(0.67%)
Day’s Range― - ―
52-Week Range$12.26 - $16.17
Previous CloseN/A
Volume378.64K
Average Volume (3M)1.93M
Market Cap
$11.77B
Enterprise Value$1.14T
Total Cash (Recent Filing)$82.59B
Total Debt (Recent Filing)$67.73B
Price to Earnings (P/E)18.4
Beta0.47
Next Earnings
May 08, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)0.16
Shares Outstanding834,604,000
10 Day Avg. Volume1,664,562
30 Day Avg. Volume1,927,640
Financial Highlights & Ratios
PEG Ratio10.58
Price to Book (P/B)2.82
Price to Sales (P/S)2.89
P/FCF Ratio78.16
Enterprise Value/Market Cap96.71
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda12.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.66
Revenue Forecast (FY)$3.76B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet & Strong ROELow leverage and consistently strong returns on equity provide durable financial flexibility. This capital efficiency supports funding R&D, M&A, and commercial expansion while absorbing cyclical or regulatory shocks, underpinning sustainable shareholder returns over the medium term.
Diversified Commercial Growth And PipelineBroad-based growth across India and emerging markets, plus semaglutide authorization and multi‑market filings, reduce reliance on any single product or region. This diversification and pipeline progress strengthen long-term revenue resilience and expand high-growth addressable markets.
Strong Liquidity And Active HedgingA net cash surplus, positive free cash flow and sizeable FX hedges provide durable financial headroom. This liquidity supports sustained R&D, capex and integration of acquisitions, and mitigates currency volatility risks that can otherwise impair international revenue and margins.
Bears Say
U.S. Biologics Regulatory SetbacksRegulatory inspection failures and CRLs materially delay entry of key biosimilars into the U.S. market. Such timing setbacks compress near‑term revenue and push out ROI on biologics investments, highlighting execution and third‑party manufacturing risk for long‑term biosimilars growth.
Weak Cash Conversion / Higher Working CapitalEarnings are less reliably converted into cash due to rising working capital and capex intensity. Persistent weaker cash conversion reduces financial flexibility, constrains reinvestment or dividends, and increases sensitivity to funding needs during product launches or regulatory delays.
Margin Pressure & Elevated SG&ASustained margin compression and higher SG&A from strategic investments and one‑offs suggest structural profitability headwinds. Combined with U.S. generics price erosion and product mix changes, this can limit long‑term margin sustainability and reduce free cash flow generation.
Dr Reddy's Laboratories News
RDY FAQ
What was Dr. Reddy's Laboratories Ltd’s price range in the past 12 months?
Dr. Reddy's Laboratories Ltd lowest stock price was $12.26 and its highest was $16.17 in the past 12 months.
What is Dr. Reddy's Laboratories Ltd’s market cap?
Dr. Reddy's Laboratories Ltd’s market cap is $11.77B.
When is Dr. Reddy's Laboratories Ltd’s upcoming earnings report date?
Dr. Reddy's Laboratories Ltd’s upcoming earnings report date is May 08, 2026 which is in 66 days.
How were Dr. Reddy's Laboratories Ltd’s earnings last quarter?
Dr. Reddy's Laboratories Ltd released its earnings results on Jan 27, 2026. The company reported $0.158 earnings per share for the quarter, beating the consensus estimate of $0.154 by $0.004.
Is Dr. Reddy's Laboratories Ltd overvalued?
According to Wall Street analysts Dr. Reddy's Laboratories Ltd’s price is currently Overvalued.
Does Dr. Reddy's Laboratories Ltd pay dividends?
Dr. Reddy's Laboratories Ltd pays a Annually dividend of $0.091 which represents an annual dividend yield of 0.64%. See more information on Dr. Reddy's Laboratories Ltd dividends here
What is Dr. Reddy's Laboratories Ltd’s EPS estimate?
Dr. Reddy's Laboratories Ltd’s EPS estimate is 0.13.
How many shares outstanding does Dr. Reddy's Laboratories Ltd have?
Dr. Reddy's Laboratories Ltd has 834,604,000 shares outstanding.
What happened to Dr. Reddy's Laboratories Ltd’s price movement after its last earnings report?
Dr. Reddy's Laboratories Ltd reported an EPS of $0.158 in its last earnings report, beating expectations of $0.154. Following the earnings report the stock price went down -0.508%.
Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd?
Currently, no hedge funds are holding shares in RDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr Reddy's Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
RDY Company Deck
RDY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a mixed but overall constructive picture: the company demonstrated resilient top-line growth (+4.4% YoY) driven by strong performance in India and emerging markets (double-digit growth) and meaningful pipeline and commercial milestones (semaglutide authorization in India, abatacept filings, European denosumab approval). Liquidity remains healthy (net cash surplus ~USD 342m) and integration of acquisitions is progressing. Offsetting these positives are margin compression, profit declines, continued U.S. generics weakness due to Lenalidomide decline, regulatory/inspection-related delays for some biosimilars (denosumab, rituximab) and elevated SG&A driven by strategic investments and a one-time labor-code provision. On balance the positive operational momentum, pipeline progress and strong cash position modestly outweigh the near-term margin and regulatory challenges.View all RDY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
1.04% Mutual Funds
2.85% Other Institutional Investors
94.94% Public Companies and
Individual Investors